12:00 AM
 | 
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GGTI-2418: Phase I started

Tigris began an open-label, dose-escalation, U.S. Phase I trial to evaluate intravenous GGTI-2418 in 25-40 patients. Tigris has exclusive, worldwide rights to...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >